TY  - JOUR
AU  - Cardoso, Fatima
AU  - Wilking, Nils
AU  - Bernardini, Renato
AU  - Biganzoli, Laura
AU  - Espin, Jaime
AU  - Miikkulainen, Kaisa
AU  - Schuurman, Susanne
AU  - Spence, Danielle
AU  - Spitz, Sabine
AU  - Ujupan, Sonia
AU  - Zernik, Nicole
AU  - Gordon, Jenn
PY  - 2020
DO  - 10.1016/j.breast.2020.04.011
UR  - http://hdl.handle.net/10668/15630
T2  - Breast (Edinburgh, Scotland)
AB  - There is a growing understanding as science evolves that different cancer types require different approaches to treatment evaluation, especially in the metastatic stages. The introduction of new metastatic breast cancer (MBC) treatments may be...
LA  - en
PB  - Churchill Livingstone
KW  - Health technology assessment
KW  - Metastatic breast cancer
KW  - Patient preferences
KW  - Policy
KW  - Stakeholders
KW  - Treatment benefit
KW  - Breast Neoplasms
KW  - Decision Making
KW  - Health Planning
KW  - Humans
KW  - Patient Preference
KW  - Policy
KW  - Quality of Life
KW  - Stakeholder Participation
KW  - Technology Assessment, Biomedical
TI  - A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments.
TY  - research article
VL  - 52
ER  -